Explore AbbVie’s latest executive share moves, award wins and workplace accolades—insight into its oncology pipeline, market‑access strategy and growth outlook.
AbbVie’s Q3 filing shows steady growth, £120 million UK R&D expansion, and new bispecific antibody data slated for ASH, driving innovation and market momentum.
AbbVie’s Q3 surge fuels growth in Humira, Skyrizi, and Jemperli, while a £120 m Oxford R&D hub expands global science, gene‑therapy partnerships, and regulatory alignment for faster, cost‑effective drug delivery.
AbbVie, Chevron, and ExxonMobil beat Q3 expectations—discover how drug sales and energy profits drive market moves amid rising inflation and BOJ policy.
AbbVie’s lutikizumab shows Phase III success for hidradenitis suppurativa and weight‑management, but regulatory, payer, and competitive hurdles remain.